A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

Inclusion Criteria Subjects must have: Normal history and physical exam. Negative ELISA for HIV. Normal cell-mediated immune responses using Merieux skin test. Normal urinalysis. Exclusion Criteria Co-existing Condition: Subjects with the following conditions are excluded: Evidence of psychological or psychiatric problems that may lead to noncompliance with study requirements. Positive syphilis serology. If serology is documented as a false positive or is due to a remote (> 6 months) treated infection, subject is eligible. Circulating hepatitis B surface antigen. Subjects with the following prior conditions are excluded: History of immunodeficiency, chronic illness, autoimmune disease, or use of immunosuppressive medications. History of anaphylaxis or other adverse reactions to vaccines. Prior Medication: Excluded: Prior HIV vaccines. Immunoglobulins or vaccines within the past 3 months. Experimental agents within the past 30 days. Prior Treatment: Excluded: Blood transfusions or cryoprecipitates within the past 3 months. Identifiable high-risk behavior for HIV infection, including: Any history of intravenous (IV) drug use within the past year. Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease) in the past 6 months. More than two sexual partners, or sexual contact with a high-risk partner, in the past 6 months.